Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06090825
Collaborator
(none)
450
1
24
18.7

Study Details

Study Description

Brief Summary

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational study

Detailed Description

Pancreatic cancer is a highly malignant gastrointestinal tumor with only a 10% overall 5-year survival rate. More than 80% of patients are already in the advanced stage when diagnosed, losing the chance of surgery. Advanced pancreatic cancer progresses rapidly and chemoradiotherapy has limited efficacy, so palliative care is thought to play an important role in the treatment process. However, due to the late development of palliative care, there is a lack of data on real-world clinical palliative care for pancreatic cancer patients in China.

This study investigates the real-world current status of palliative care for pancreatic cancer patients by sending a web questionnaire to the doctors from the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland. The survey aims to obtain the real status of palliative care and achieve a comprehensive understanding of how to develop palliative care in hospitals.

The questionnaire includes both subjective standards like the surgeons' opinion on the development of palliative therapy and objective standards such as dedicated beds and teams for palliative care.

Study Design

Study Type:
Observational
Anticipated Enrollment :
450 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Real World Status of Palliative Care for Pancreatic Cancer Patients in China-a National Multi-center Cross-sectional Survey
Actual Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Pancreatic cancer patients

Other: Observational study
Observational study

Outcome Measures

Primary Outcome Measures

  1. Descriptions and scores of real status of hospice care in different hospitals [1 month]

    The primary outcome is objective standards and subjective scores of current status of palliative care to qutify the development of palliative care of different hospitals. The score is evaluated by a follow-up questionnaire. The maximum and minimum score is 10 and 0, respectively.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Doctors from the General Surgery Department in Chinese public tertiary teaching hospitals and public primary care units

  • Approval to participate

  • Participants with a valid and complete questionnaire evaluated by 2 experienced surgeons

Exclusion Criteria:
  • Refusal to participate

  • Participants with an invalid or incomplete questionnaire

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking Union Medical College Hospital Beijing Beijing China 100730

Sponsors and Collaborators

  • Peking Union Medical College Hospital

Investigators

  • Study Chair: Qiaofei Liu, Department of General Surgery, Peking Union Medical College Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Qiaofei Liu, Department director assistant, clinical chief professor, Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT06090825
Other Study ID Numbers:
  • K4602
First Posted:
Oct 19, 2023
Last Update Posted:
Oct 19, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Qiaofei Liu, Department director assistant, clinical chief professor, Peking Union Medical College Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 19, 2023